MedTrace Logo

Safety and Tolerability Study of SHP626 in Overweight and Obese Adults

NCT02287779 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2019-03-26

Study results available
· View outcomes & findings →

Summary

This study will investigate the safety and tolerability of daily dosing regimens of SHP626 in overweight and obese adults.

Conditions

  • Non-Alcoholic Steatohepatitis

Interventions

DRUG

SHP626

DRUG

Placebo

Sponsors & Collaborators

  • Mirum Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Study Director · Mirum

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-01-19
Primary Completion
2015-06-19
Completion
2015-06-19

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02287779 on ClinicalTrials.gov